Press release
AATD Augmentation Therapy Market: Grifols, S.A., Kamada Ltd, Shire plc (Baxalta), and CSL Limited. Grifols accounted for the highest share in terms of revenue in 2018
AATD Augmentation Therapy Market Size, Share and Global Trend by Product Type
Sample Pages: https://www.fortunebusinessinsights.com/enquiry/sample/aatd-augmentation-therapy-100169
Grifols SA’s AlfaCare Program Has Had a Positive Impact on the Global Market
In November 2018, Grifols Sa introduced AlfaCare, a therapy program aimed at providing training and counselling to patients diagnosed with AATD. Grifols stated that with AlfaCare, it aims to encourage new habits in AATD patients and help them manage their disease properly. Research studies have proven that a huge percentage of people diagnosed with AATD were unaware about the symptoms, effects, and ways to treat the disorder. AlfaCare was launched to overcome all such shortcomings and improve the quality of patient care, thereby ascertaining reduced fatality rate of AATD. Thus, AlfaCare has transformed AATD augmentation therapies worldwide and is likely to boost the global AATD augmentation therapy market in the forecast period.
North America to Dominate the Global Market
Rising number of AATD cases in North America is fuelling the demand for AATD augmentation therapy in this region. This in turn has led to the growth of AATD augmentation therapy market in North America and is likely to favor growth of the market in this region through the forecast period. There have been significant improvements in AATD diagnostic techniques used in many parts of Asia Pacific. Furthermore, the emphasis on AATD by the government in Asia Pacific is likely to enable growth in the regional market in the forthcoming years. Despite North America’s dominance, Asia Pacific will emerge as the fastest growing region in the forecast period.
Speak to Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/aatd-augmentation-therapy-100169
New Biological Approval for Prolastin C to Enable Growth of Global Market
In September 2017, Grifols received biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C. The inclusion of this liquid may enable the launch of an additional alternative to the existing therapy. Clinical trials and proven efficacy have favored the approval for this product. With the latest addition to its product portfolio, Grifols will increase its stronghold in the global AATD augmentation therapy market. As Grifols’ products are used by a huge percentage of the global population, its new product approval will have a direct impact on the global market. Backed by successful therapies and efficient products, Grifols has accounted for the highest share in the global market. Recent product approvals have favoured the company and accounting to this, Grifols is likely to emrge dominant in the forecast period as well.
Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/aatd-augmentation-therapy-100169
About us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email us: sales@fortunebusinessinsights.com
Website: https://www.fortunebusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AATD Augmentation Therapy Market: Grifols, S.A., Kamada Ltd, Shire plc (Baxalta), and CSL Limited. Grifols accounted for the highest share in terms of revenue in 2018 here
News-ID: 1724775 • Views: …
More Releases from Fortune Business Insights
Future of Renewable Energy Market Insights: Growth Drivers, and Regional Develop …
Global Renewable Energy Market Overview
The global renewable energy market size was valued at USD 954 billion in 2023. The market is projected to grow from USD 1,020.94 billion in 2024 to USD 1,574.17 billion by 2032, exhibiting a CAGR of 5.56% during the forecast period. Asia Pacific dominated the renewable energy market with a market share of 67.76% in 2023. The Renewable energy market in the U.S. is projected to…
DC Drives Market Overview: Opportunities, Growth Drivers, and Key Applications
Market Overview
The global DC drives market size was valued at USD 4.34 billion in 2018 and is projected to reach USD 9.23 billion by 2032, exhibiting a CAGR of 5.59% during the forecast period of 2019-2032. Asia Pacific dominated the global market with a share of 28.8% in 2018. The DC drives market in the U.S. is projected to grow significantly, reaching an estimated value of USD 1.59 billion by…
Humanoid Robots Market: An In-depth B2B Analysis of Size, Share, and Future Grow …
Brief Market Overview:
The global humanoid robots market is rapidly transitioning from a nascent field into a major growth sector, with its value escalating from USD 2.43 billion in 2023 to a projected USD 66.0 billion by 2032, demonstrating a remarkable CAGR of 45.5%.
These complex machines, which merge mechanical, electrical, and software engineering, are moving beyond research labs into real-world applications across industrial, service, and household sectors. This explosive growth…
Methanol Market Poised for Remarkable Growth, set to Reach USD 46.32 billion by …
The global methanol market size was valued at USD 31.26 billion in 2023. It is projected to grow from USD 32.70 billion in 2024 to USD 46.32 billion by 2032, exhibiting a CAGR of 4.5% during the forecast period.
The global methanol market size is set to gain traction from the urgent need to lower environmental pollution caused by the surging usage of heavy fuels, such as diesel and gasoline. Pollution…
More Releases for AATD
Alpha-1 Antitrypsin Deficiency Pipeline: 40+ Pioneering Companies Driving Innova …
The Alpha-1 antitrypsin deficiency market is entering a new era of innovation, driven by over 20 leading biotech and pharma players, including Intellia Therapeutics, Apic Bio, Linton Pharm, Z Factor Limited, Vertex Pharmaceuticals, Grifols, and Kamada. These visionaries are reshaping treatment paradigms with next-gen therapies that promise greater precision and better outcomes.
DelveInsight's "Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Alpha-1…
Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Revenue, Trend …
New York, United States, -
The Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market size is estimated to grow at a CAGR of 6.2% between 2023 and 2032. The growth of the market depends on several factors, including the increasing prevalence of Alpha-1 Antitrypsin Deficiency, advancements in treatment options, and rising awareness about this genetic disorder. Alpha-1 Antitrypsin Deficiency is a genetic condition that can lead to lung and liver…
Globally, More than 12+ Companies are Developing 12+ Therapies in Alpha1-Antitry …
"Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alpha-1 Antitrypsin Deficiency Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the…
What's driving the Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Ma …
The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the foreacast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period. The Global “AATD (Alpha-1 Antitrypsin Deficiency) Augmentation Therapy” Market has been supported by late FDA endorsement for Prolastin-C. According to…
Alpha-1 antitrypsin deficiency (AATD) Market 2020 Overview by Experts to 2026
Alpha-1 antitrypsin deficiency (AATD) Pipeline Insight, 2020
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Alpha-1 antitrypsin deficiency (AATD) Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of…
What's driving the Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Ma …
The Global Alpha-1 Antitrypsin Deficiency (Aatd) Augmentation Therapy Market has been supported by late FDA endorsement for Prolastin-C. According to a report published by Fortune Business Insights, titled “AATD Augmentation Therapy: Global Analysis, Insights and Forecast, 2019-2026”, the market will be valued at US$ 1959.8 Mn by the end of 2025.
Sample PDF Brochure @ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/alpha-1-antitrypsin-deficiency-aatd-treatment-market-100189
Some of the major companies that are present in the Global Alpha-1 Antitrypsin Deficiency Treatment Market…
